Report an error

Spotted something inaccurate in “Reanalysis Suggests ~70% of Alirocumab's CV Benefits Attributable to Lp(a) Reduction, Not LDL-C”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.